Context. Little is known about the phenotypic and molecular characteristics associated with changes over time in fatigue and lack of energy in patients with breast cancer.
Introduction
Fatigue is the most common symptom reported by patients who undergo treatment for breast cancer. 1 Although more than 90% of patients diagnosed with breast cancer will undergo surgery, only a limited number of longitudinal studies have evaluated for preoperative levels of fatigue and changes in fatigue after surgery.
2e5 Across these studies, a variety of demographic (e.g., younger age 3 ) and clinical (e.g., partial mastectomy, 6 poorer functional status 4,6 ) characteristics, and psychological factors (e.g., presurgical expectancies for fatigue, 3 introversion 5 ) were associated with higher levels of fatigue after surgery. In these studies, the length of post-surgical follow-up ranged from one week 3 to one year. 6 Only one study was identified that used a type of growth mixture modeling (GMM) to identify subgroups of breast cancer patients (n ¼ 290) with distinct fatigue trajectories. 2 Using fatigue assessments done before and at four and five months after surgery, groups of patients with persistently high (21%) and persistently low (79%) levels of fatigue were identified. Patients in the high group were more likely to report lower levels of physical activity and higher levels of anxiety. No demographic or clinical characteristics were associated with membership in the higher fatigue group. Although this study provides important information on persistent fatigue, only three assessments were done (i.e., four weeks before surgery and four and eight months after surgery) and the confidence intervals (CIs) were wide, which suggests that a larger sample could result in more reliable estimates.
In oncology, fatigue is defined as a distressing, persistent sense of physical, emotional, and/or cognitive tiredness for exhaustion related to cancer or cancer treatment that is not proportional to recent activity and interferes with usual functioning. 7 In contrast, energy can be defined as an individual's potential to perform physical and mental activity. 8 As noted in our previous publication, 9 an increasing body of evidence suggests that fatigue and energy are distinct but related constructs. 8, 10, 11 For example, instruments like the Profile of Mood States (POMS) 12 have separate scales for fatigue-inertia and energy-vigor. The energy subscale of the POMS evaluates the intensity of energy using a variety of descriptors (e.g., energetic, full of pep). Like the POMS, the Lee Fatigue Scale (LFS) has two subscales (i.e., a fatigue subscale with 13 items and an energy subscale with five items). The LFS asks participants to rate their level of energy using a 0 to 10 numeric rating scale (NRS) on five descriptors (i.e., energetic, active, vigorous, efficient, lively). The original psychometric evaluation of the LFS identified these two distinct subscales. 13 In addition, a recent Rasch analysis of the LFS found that fatigue and energy represented different symptoms. 14 Only one study was identified that evaluated decrements in energy in patients before breast cancer surgery. 15 In this study, although 32% of the women reported clinically meaningful levels of fatigue, nearly 50% of the patients reported clinically meaningful decrements in energy levels before surgery. No studies were identified that evaluated for subgroups of patients with distinct energy trajectories from before to six months after breast cancer surgery.
Although some progress has been made in evaluating the role of inflammatory mediators in the development and maintenance of fatigue, recent reviews of fatigue in patients with cancer recommend that additional research be done to establish the underlying mechanisms for fatigue. 1, 16, 17 In all these reviews, emphasis is placed on understanding the molecular mechanisms that underlie the development of persistent fatigue in oncology patients.
Cytokines, their receptors, and transcriptional regulators are one class of polypeptides that mediate inflammatory processes (for reviews, see Fagundes et al., 18 Morris et al., 19 Poon et al. 20 ). In several studies, 21e24 genetic and epigenetic mechanisms involved in inflammation were associated with fatigue in oncology patients. Only one study was found that reported on associations between polymorphisms in cytokine genes and decrements in energy in oncology patients undergoing radiation therapy and their family caregivers. 9 This preliminary evidence provides support for the role of molecular mechanisms involved in inflammatory processes, particularly cytokines, in the etiology of fatigue and decrements in energy in oncology patients.
Given the paucity of longitudinal studies that aimed to determine distinct phenotypes for fatigue and energy after breast cancer surgery and the need for more molecular-based studies, the purposes of this study, in a sample of women (n ¼ 398) who were assessed before and monthly for six months after surgery were to: identify subgroups (i.e., latent classes) of women with distinct fatigue and energy trajectories, evaluate for differences in phenotypic characteristics between the latent classes for fatigue and energy, and evaluate for associations between polymorphisms in genes for pro-and anti-inflammatory cytokines, their receptors, and their transcriptional regulators and latent class membership. We hypothesized that at least two latent classes would be identified for each symptom using GMM and distinct phenotypic characteristics and genetic polymorphisms would be associated with higher fatigue and lower energy latent class membership.
Materials and Methods

Patients and Settings
This analysis is part of a larger, longitudinal study that evaluated neuropathic pain and lymphedema in women who underwent breast cancer surgery. The study methods are described in detail elsewhere. In brief, patients were recruited from breast care centers located in a Comprehensive Cancer Center, two public hospitals, and four community practices.
Patients were eligible to participate if they were adult women ($18 years) who were scheduled to undergo unilateral breast cancer surgery; were able to read, write, and understand English; agreed to participate; and gave written informed consent. Patients were excluded if they were having bilateral breast cancer surgery or had distant metastasis at the time of diagnosis. A total of 516 patients were approached, 410 were enrolled (response rate 79.5%), and 398 completed the enrollment assessment. The most common reasons for refusal were too busy, overwhelmed with the cancer diagnosis, or insufficient time available to do the enrollment assessment before surgery.
Instruments
The demographic questionnaire obtained information on age, marital status, education, ethnicity, employment status, and living situation. Patients rated their functional status using the Karnofsky Performance Status (KPS) scale that ranged from 30 (I feel severely disabled and need to be hospitalized) to 100 (I feel normal; I have no complaints or symptoms).
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The Self-Administered Comorbidity Questionnaire (SCQ) was used to evaluate comorbidity. 30 Patients were asked to indicate if they had one of 13 common medical conditions; if they received treatment for it (proxy for disease severity); and did it limit their activities (indication of functional limitations). For each condition, a patient can receive a maximum of 3 points. The total SCQ score can range from 0 to 39 points. The SCQ has well-established validity and reliability.
31,32
The LFS consists of 18 items designed to assess physical fatigue and energy. 13 Each item was rated on a 0 to 10 NRS. Total fatigue and energy scores were calculated as the mean of the 13 fatigue items and the five energy items, with higher scores indicating greater fatigue severity and higher levels of energy. Patients were asked to rate each item based on how they felt ''right now.'' The LFS has been used with healthy individuals 13, 33 and in patients with cancer and HIV. Cutoff scores of 4.4 or more and 4.8 or less indicate clinically meaningful levels of fatigue severity and low levels of energy, respectively. 38 The LFS has wellestablished validity and reliability. 13, 33 In the present study, Cronbach alphas for the fatigue and energy scales were 0.96 and 0.93, respectively.
Study Procedures
The study was approved by the Committee on Human Research at the University of California, San Francisco, and by the institutional review boards at each of the study sites. During the preoperative visit, a clinician explained the study, determined the patient's willingness to participate, and introduced her to the research nurse. The research nurse met with the woman, determined eligibility, and obtained written informed consent before surgery. After obtaining consent, patients completed the enrollment questionnaires an average of four days before surgery. Patients completed the LFS at enrollment and monthly for six months (i.e., seven assessments). Medical records were reviewed for disease and treatment information.
Genomic Analyses
Gene Selection. Cytokines, their receptors, and their transcriptional regulators are classes of polypeptides that mediate pro-and anti-inflammatory processes. Cytokine dysregulation is associated with fatigue (for reviews, see Bower and Ganz, 1 Saligan et al., 17 Barsevick et al.
39
). Pro-inflammatory genes promote systemic inflammation and include chemokine (C-C-C motif) ligand 8 (CXCL8, previous gene symbol interleukin 8 [IL8]), interferon gamma [IFNG], IFNG receptor 1 (IFNGR1), IL1 receptor 1 [IL1R1], IL2, IL17A, and members of the tumor necrosis factor (TNF ) family (i.e., lymphotoxin alpha [LTA], TNF ). Antiinflammatory genes suppress the activity of proinflammatory cytokines and include IL1R2, IL4, IL10, and IL13. Of note, IFNG1, IL1B, and IL6 possess proand anti-inflammatory functions. Nuclear factor kappa beta 1 (NFKB1) and NFKB2 are transcriptional regulators of these cytokine genes. 40 All genes were identified according to the approved symbol stored in the Human Genome Organization Gene Nomenclature Committee database (http://www.genenames.org).
Blood Collection and Genotyping. Of the 398 patients who completed the enrollment assessment, 310 provided a blood sample from which DNA could be isolated from peripheral blood mononuclear cells. Genomic DNA was extracted from peripheral blood mononuclear cells using the PUREGene DNA Isolation System (Invitrogen, Carlsbad, CA). DNA was quantitated with a Nanodrop Spectrophotometer (ND-1000) and normalized to a concentration of 50 ng/L. Genotyping was performed blinded to clinical status, and positive and negative controls were included. Samples were genotyped using a custom array on the Golden Gate genotyping platform (Illumina, San Diego, CA) and processed according to the standard protocol using GenomeStudio (Illumina).
SNP Selection. A combination of tagging singlenucleotide polymorphism (SNPs) and literaturedriven SNPs were selected for analysis. Tagging SNPs were required to be common (i.e., a minor allele frequency $0.05) in public databases. SNPs with call rates of less than 95% or Hardy-Weinberg P-values of <0.001 were excluded. As shown in Supplementary 48 The fatigue and energy data were analyzed separately. Descriptive statistics and frequency distributions were generated for sample characteristics. Independent-sample t-tests, Mann-Whitney U tests, chi-squared analyses, and Fisher exact tests were used to evaluate for differences in demographic and clinical characteristics between the two latent classes. A P-value of <0.05 was considered statistically significant.
Unconditional GMM with robust maximum likelihood estimation was carried out to identify latent classes with distinct fatigue and energy trajectories using Mplus, version 5.21 (Muth en & Muth en, Los Angeles, CA). These methods are described in detail elsewhere. 28 In brief, a single growth curve that represented the ''average'' change trajectory was estimated for the whole sample. Then, the number of latent growth classes that best fit the data was identified using guidelines recommended in the literature. 
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For SNPs that were members of the same haploblock, haplotype analyses were conducted to localize the association signal within each gene and to determine if haplotypes improved the strength of the association with the phenotype. Haplotypes were constructed using the program PHASE, version 2.1. 53 To improve the stability of haplotype inference, the haplotype construction procedure was repeated five times using different seed numbers with each cycle. Only haplotypes that were inferred with probability estimates of 0.85 or more, across the five iterations, were retained for downstream analyses. Only inferred haplotypes that occurred with a frequency estimate of $15% were included in the association analyses, assuming a dosage model (i.e., analogous to the additive model).
Ancestry informative markers were used to minimize confounding because of population stratification.
54e56
Homogeneity in ancestry among patients was verified by principal component (PC) analysis, 57 using HelixTree (GoldenHelix, Bozeman, MT). Briefly, the number of PCs was sought that distinguished the major racial/ethnic groups in the sample by visual inspection of scatter plots of orthogonal PCs (i.e., PC1 vs. PC2, PC2 vs. PC3). This procedure was repeated until no discernable clustering of patients by their selfreported race/ethnicity was possible (data not shown). The first three PCs were selected to adjust for potential confounding because of population substructure (i.e., race/ethnicity) by including them in all the logistic regression models. One hundred six ancestry informative markers were included in the analysis.
For association tests, three genetic models were assessed for each SNP: additive, dominant, and recessive. Barring trivial improvements (i.e., delta <10%), the genetic model that best fit the data, by maximizing the significance of the P-value, was selected for each SNP. Logistic regression analysis, that controlled for significant covariates, and genomic estimates of and self-reported race/ethnicity, was used to evaluate the associations between genotype and fatigue and energy class membership. Only those genetic associations identified as significant from the bivariate analyses were evaluated in the multivariate analyses. A backward stepwise approach was used to create a parsimonious model. Except for genomic estimates of and self-reported race/ethnicity, only predictors with a P-value of <0.05 were retained in the final model. Genetic model fit and both unadjusted and covariate-adjusted odds ratios were estimated using STATA, version 13.
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As was done in our previous studies, 9,23,25,27,58e69 based on the recommendations in the literature, 70, 71 and the implementation of rigorous quality controls for genomic data, the nonindependence of SNPs/haplotypes in LD, and the exploratory nature of the analyses, adjustments were not made for multiple testing. In addition, significant SNPs identified in the bivariate analyses were evaluated further using logistic regression analyses that controlled for differences in phenotypic characteristics, potential confounding because of population stratification, and variations in other SNPs/haplotypes within the same gene. Only those SNPs that remained significant were included in the final presentation of the results. Therefore, the significant independent associations reported are unlikely to be due solely to chance. Unadjusted (bivariate) associations are reported for all the SNPs that passed quality control criteria in Supplementary Table 1, to allow for subsequent comparisons and meta-analyses.
Results
GMM Analysis for Fatigue
Two distinct latent classes of fatigue trajectories were identified using GMM (Fig. 1a) . A two-class model was selected because its Bayesian Information Criterion was smaller than the one-class and threeclass models (Table 1 ). As listed in Table 2 , the majority of the patients were classified into the Higher Fatigue class (n ¼ 244, 61.5%). These patients had estimated fatigue scores that were high before surgery (3.90) and remained high over the six months of the study. Patients in the Lower Fatigue class (n ¼ 153, 38.5%) had estimated fatigue scores that were lower at enrollment (1.60) and that gradually decreased over time.
Differences in Demographic and Clinical Characteristics Between the Fatigue Classes
As summarized in Table 3 , patients in the Higher Fatigue class were significantly younger and had more education, a lower KPS score, a higher SCQ score, and a higher number of lymph nodes removed. In addition, a higher percentage of patients in the Higher Fatigue class had received neoadjuvant chemotherapy (CTX) before surgery and adjuvant CTX during the first six months after breast cancer surgery.
Candidate Gene Analyses for Fatigue
As summarized in Supplementary Table 1, no associations with fatigue latent class membership were observed for SNPs in CXCL8, INFGR1, IL1R2, IL2, IL4, IL6, IL13, 1L17 A, NFKB1, NFKB2, or members of the TNF family (i.e., LTA, TNF ). However, genotype frequencies were significantly different between the two latent classes for eight SNPs spanning three genes: IFNG rs2069718, IL1B rs1143629, IL1B rs1143627, IL1B rs16944, IL1B rs1143623, IL10 rs3024496, IL10 rs1878672, and IL10 rs3024491.
Regression Analyses for IFNG, IL1B, and IL10 Genotypes and Lower vs. Higher Fatigue Classes
To better estimate the magnitude (i.e., odds ratio) and precision (95% CI) of genotype on the odds of belonging to the higher compared with the Lower fatigue class, multivariate logistic regression models were fit. In these regression analyses, that included genomic estimates of and self-reported race/ethnicity, the only phenotypic characteristics that remained significant in the multivariate model were age (in five-year increments), KPS score (in 10 unit increments), SCQ score, and receipt of CTX in the six months after surgery.
Two SNPs spanning two different genes remained significant in the multivariate logistic regression analyses (Table 4 , Figs. 2a and 2b). For IL1B rs16944 and IL10 rs3024496, a recessive model fit the data best (P ¼ 0.002). In the regression analysis for IL1B rs16944, carrying two doses of the rare A allele (i.e., GG þ GA vs. AA) was associated with a 2.98-fold higher odds of belonging to the Higher Fatigue class. In the regression analysis for IL10 rs3024496, carrying two doses of the rare C allele (i.e., TT þ TC vs. CC) was associated with a 66% decrease in the odds of belonging to the Higher Fatigue class.
GMM Analysis for Energy
Two distinct latent classes of energy trajectories were identified using GMM (Fig. 1b) . A two-class model was selected because its Bayesian Information Criterion was smaller than the one-class and three-class models ( Table 1 ). As listed in Table 2 , the majority of the patients were classified into the Lower Energy class (n ¼ 270, 68.0%). These patients had estimated energy scores that were low before surgery (4.35) and remained low over the six months of the study. Patients in the Higher Energy class (n ¼ 127, 32.0%) had estimated energy scores that were higher at enrollment (5.82) and that gradually increased over time.
Differences in Demographic and Clinical Characteristics Between the Energy Classes
As summarized in Table 5 , patients in the Lower Energy class had a lower KPS score and a higher SCQ score. In addition, the percentage of patients based on their stage of disease differed between the two energy classes. However, post hoc contrasts failed to identify the subgroups that differed between the classes. 
Candidate Gene Analyses for Energy
As summarized in Supplementary Table 1, no associations with energy class membership were found for SNPs in any gene except IL1R1. The genotype frequency was significantly different between the two latent classes for one SNP: IL1R1 rs2110726.
Regression Analyses for IL1R1 Genotype and Higher vs. Lower Energy Classes
To better estimate the magnitude (i.e., odds ratio) and precision (95% CI) of genotype on the odds of belonging to the Higher compared with the Lower Energy class, a multivariate logistic regression model was fit. In this regression analysis that included genomic estimates of and self-reported race/ethnicity, the only phenotypic characteristics that remained significant in the multivariate model were KPS score (in 10-unit increments) and receipt of CTX in the six months after surgery.
In the multivariate logistic regression analysis, the association between IL1R1 rs2110726 and the energy phenotype remained significant (Table 6, Fig. 3 ). For this SNP, a dominant model fit the data best (P ¼ 0.021). In the regression analysis, carrying one or two doses of the rare T allele (i.e., CC vs. CT þ TT) was associated with a 50% decrease in the odds of belonging to the Lower Energy class.
Overlap Between the Fatigue and Energy Latent Classes
An analysis of membership in the fatigue and energy classes in this study revealed that of the 397 patients evaluated: 16.6% (n ¼ 66) were in both the Lower Fatigue and Lower Energy classes; 21.9% 
Discussion
This study is the first to use GMM to identify subgroups of breast cancer patients with distinct trajectories of fatigue and energy and evaluate for associations between a number of cytokine genes and these distinct phenotypes. Because less is known about decrements in energy after breast cancer surgery, this section begins with a discussion of the fatigue findings. In the section that discusses the energy findings, similarities and differences between the two symptoms in phenotypic characteristics and molecular markers are described.
Fatigue Findings
In the present study, 62% of the patients reported fatigue scores at the clinically meaningful cutoff score that occurred before surgery and persisted for six months after surgery. This finding contrasts with the previous study by Bodtcher et al. 2 who reported that only 21% of their sample reported high levels of fatigue before surgery and that their fatigue decreased at three months and then returned to pretreatment levels at eight months after surgery. Although the demographic and clinical characteristics of the two samples were relatively similar, differences in the instruments used to assess fatigue and in the statistical approaches used to create the latent classes may explain the difference in percentages of patients in the higher fatigue class.
In terms of demographic characteristics, patients who were younger and had more years of education were more likely to be in the higher fatigue class. Although our findings are consistent with those of Bodtcher et al. 2 and Montgomery et al., 3 they contrast with other studies that found no association 4e6 between age and severity of fatigue in women after breast cancer surgery. In the study by Montgomery et al., 3 mediational analyses demonstrated that preoperative expectations of postoperative levels of fatigue accounted in part for the effects of age on the severity of postoperative fatigue. The authors commented that their findings could be explained by Social Learning Theory, which suggests that an individual's previous experiences with fatigue might shape one's expectancies for the symptom. 72, 73 They hypothesized that older patients may have had previous experiences with surgery and/or fatigue that lowered their expectations for fatigue. An equally important consideration in all the studies cited above is that the mean age of the patients ranged from late 40s to late 50s. Therefore, additional studies are needed that evaluate the association between age and changes in fatigue severity after breast cancer surgery in older age groups.
Although two studies found no association between education and fatigue severity in breast cancer survivors and women who underwent adjuvant treatment, 74, 75 our findings are consistent with those of Huang et al. 6 who evaluated fatigue trajectories in women who were followed for 12 months after breast cancer surgery. Given these inconsistent findings and the relatively high levels of education in the current and previous studies, 74,75 additional research is warranted to determine the specific factors associated with educational attainment (e.g., different levels of social responsibility, different employment opportunities) that may contribute to variations in fatigue severity.
Across a series of studies, the evidence is clear that a higher number of comorbidities, poorer performance status, and higher fatigue severity before the initiation of cancer treatment are associated with worse fatigue trajectories or membership in the higher fatigue class (for review, see Bower and Ganz 1 ). Although stage of disease and type of surgery were not associated with membership in the Higher Fatigue class, in our study, patients who had a higher number of lymph nodes removed and those who received neoadjuvant or adjuvant CTX were more likely to be in the Higher Fatigue class. An examination of the clinical characteristics that predicted higher fatigue severity in the four studies that evaluated patients after breast cancer surgery 2e5 reveal a rather disparate list of risk factors. These inconsistent findings can be partially explained by the number and types of demographic, clinical, symptom, and psychological characteristics that were placed in the various types of multivariate analyses. Future meta-analyses and larger studies with a more comprehensive list of potential predictors would provide insights into the characteristics that clinicians need to assess to identify breast cancer patients who are at higher risk for more severe fatigue.
IL1B is a pro-inflammatory cytokine that is synthesized in a variety of cells including circulating monocytes and tissue macrophages. In our study, patients who were homozygous for the rare A allele in IL1B rs16944 were more likely to be classified in the higher fatigue class. This SNP lies upstream of the IL1B gene. It lies in a region of histone modification that is suggestive of regulatory activity (i.e., H3K27Ac) and to a lesser extent in a region associated with promoters (i.e., H3K4Me1). However, based on available data in ENCODE, because this region does not contain a DNase Hypersensitivity Cluster or evidence of a transcription binding site, the location of any nearby regulatory DNA elements remains inconclusive. This SNP has been evaluated in a number of studies of fatigue in oncology patients. In contrast to our findings, in a study of 33 fatigue and 14 non-fatigued breast cancer survivors, 76 patients who were heterozygous or homozygous for the rare T allele (A allele in our study) were more likely to be in the non-fatigued group that was assessed using the Multidimensional Fatigue Symptom Inventory. 77, 78 In other studies of newly diagnosed breast cancer patients who recently completed treatment, 22 breast cancer survivors, 79 and men with prostate cancer who underwent RT, 80 no associations were found with IL1B rs16944 and the fatigue phenotype. These inconsistent findings may be related to the instruments used to assess fatigue, the methods used to create the ''fatigue phenotype'' (e.g., dichotomization using a cutpoint vs. latent class analysis), and/or the timing of the assessment of fatigue in relationship to the patient's disease trajectory (e.g., active treatment vs. survivorship). IL10 is an anti-inflammatory cytokine that regulates the growth and differentiation of B cells, natural killer cells, and cytotoxic, helper, and regulatory T cells. 81 In our study, patients who were homozygous for the rare C allele in IL10 rs3024496 were less likely to be in the higher fatigue class. This SNP is in a 3 0 untranslated region of the fifth exon of IL10. It is upstream from four TargetScan miRNA that are predicted to be putative miRNA regulatory sites and may be involved in miRNA regulatory actions. However, based on ENCODE data, little support exists for transcription factor binding in this region. Consistent with the findings from the present study, this polymorphism was associated with increased production of IL10 in cell culture. 82 In addition, in a recent study, 83 the IL10 pathway was found to be differentially expressed between patients with breast cancer who reported low compared with high levels of evening fatigue during CTX.
Energy Findings
In the present study, 68.0% of the patients reported energy scores that were below the cutoff score for clinically meaningful decrements in energy levels (i.e.,
#4.8).
Of note, these decrements in energy levels persisted in the Lower Energy class over the six months of the study. Comparisons of these findings with our previous study of patients and family caregivers 9 are difficult because diurnal variations in energy levels were not evaluated in the present study.
Similar to the fatigue findings, in the bivariate analyses, a lower KPS score, a higher SCQ score, and receipt of CTX during the six months after breast cancer surgery were associated with membership in the Lower Energy class. In addition, although stage of disease was associated with membership in the Lower Energy class (but not fatigue class membership) because of the relatively small sample sizes for the highest stage of disease, post hoc contrasts failed to identify subgroup differences. Again, although direct comparisons with our previous study are not possible, 9 a lower KPS score was associated with membership in the Low Morning and Moderate Evening energy classes. In both studies, KPS scores were approximately 90, which suggest that even with high functional status scores, some patients can experience significant decrements in energy levels.
Two additional characteristics warrant consideration. First, for both fatigue and energy, the receipt of adjuvant CTX was associated with membership in the class with the poorer outcomes. Although higher levels of fatigue are associated with the receipt of CTX, 84e86 this study is the first to document an association between receipt of adjuvant CTX and decrements in energy levels. Second, for both symptoms, clinically meaningful levels of fatigue and decrements in energy levels, before surgery, were associated with membership in the Higher Fatigue and Lower Energy classes, respectively. Taken together, these findings suggest that clinicians need to assess for both fatigue severity and decrements in energy levels before and after breast cancer surgery.
Only one SNP in the IL1R1 gene was associated with membership in the Lower Energy class. In this study, patients who were heterozygous or homozygous for the rare T allele in rs2110726 were less likely to be in the Lower Energy class. This SNP is located in the 3 0 untranslated of the IL1R1 gene. It is 35 bases 301) . For each model, the first three principal components identified from the analysis of ancestry informative markers, and self-reported race/ethnicity, were retained in all models to adjust for potential confounding because of race/ethnicity (data not shown). For the regression analysis, predictors evaluated in the model included genotype (IL1R1 rs2110726: CC vs. CT þ TT, functional status (KPS score in 10-unit increments) and receipt of chemotherapy within six months after surgery. Fig. 3 . Differences between the energy latent classes in the percentages of patients who were homozygous for the common allele (CC) or heterozygous or homozygous for the rare allele (CT þ TT) for rss110726 in interleukin 1 receptor 1 (IL1R1). Values are plotted as unadjusted proportions with corresponding P-value.
upstream from a polymorphic CpG methylation site (i.e., rs200426703). Although population data are not available for rs200426703 directly, rs2110726 is in high LD (R 2 ¼ 0.0232341, D 0 ¼ 1.0) with an SNP (i.e., rs3732134) that is 30 bases downstream from the methylated site (i.e., 65 bases downstream from rs2110726 and flanking rs200426703; see Supplementary Fig. 1 ). Methylated sites may be involved in gene regulation 87 and methylation may be allelic specific. 88 The strong LD observed between the SNPs flanking this region including the methylated polymorphic site suggests that rs2110726 may be a proxy for the genotype at the methylated site (i.e., rs200426703). Therefore, polymorphisms in rs2110726 may be related to any gene regulation activity that may occur at the polymorphic methylated site. In a previous study with the same sample, 25 patients who were heterozygous or homozygous for the rare T allele had a lower odds of reporting preoperative breast pain. Taken together, these findings are consistent with studies of IL1 function in mice, in which removal of IL1R function or blockade of IL1A led to a decrease in inflammation and pain behaviors. 89 Additional functional studies are needed to determine if the minor allele of rs2110726 is associated with a decrease in IL1R1 function and, therefore, a decrease in the pro-inflammatory effects of IL1A.
Limitations
Several study limitations need to be acknowledged. Although a growing body of evidence suggests that diurnal variations in both fatigue and energy warrant consideration in future studies, 9, 36, 38, 85, 86, 90, 91 in the present study, patients were asked to evaluate their levels of fatigue and energy at the time they completed the questionnaire. In addition, because most patients had early-stage breast cancer, differences in fatigue and energy class memberships associated with stage of disease could not be evaluated. Third, no direct measurements of systemic levels of inflammatory markers were obtained to provide additional information on the underlying mechanisms for fatigue severity and decrements in energy. Finally, the genetic associations identified in this study warrant confirmation in future studies, and functional studies are needed to confirm the impact of these polymorphisms on inflammatory mediators.
Conclusions
Findings from this study suggest that within each latent class, the severity of fatigue and decrements in energy were relatively stable from before to six months after breast cancer surgery. In addition, distinct phenotypic characteristics and genetic polymorphisms were associated with membership in the higher fatigue and lower energy classes. Although these findings warrant confirmation in future studies, the phenotypic and genetic findings from this study support the growing body of literature that suggests that fatigue and energy are distinct but related symptoms.
8e11 Additional research is warranted to evaluate for differences in the underlying mechanisms for both symptoms. Future studies can focus on an evaluation of additional immune pathways and molecular markers of metabolic and neuroendocrine function. 17 A better understanding of the molecular mechanisms that underlie these two symptoms could lead to the earlier identification of high-risk patients and the development and testing of novel mechanistically based interventions. 0.269 C > T n/a n/a n/a n/a n/a n/a IL4 rs2070874 132674017 5 0.245 C > T n/a n/a n/a n/a n/a n/a IL4 rs2227284 132677032 5 0.387 C > A n/a n/a n/a n/a n/a n/a IL4 rs2227282 132677486 5 0.390 C > G n/a n/a n/a n/a n/a n/a IL4 rs2243263 132677606 5 0.124 C > G 2.202 0.333 A 0.503 0.778 A IL4 rs2243266 132678096 5 0.237 G > A n/a n/a n/a n/a n/a n/a IL4 rs2243267 132678193 5 0.237 G > C n/a n/a n/a n/a n/a n/a (Continued)
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